Altace
$ 40,00 – $ 322,00Price range: $ 40,00 through $ 322,00
Amalaki
$ 42,00 – $ 72,00Price range: $ 42,00 through $ 72,00
Altraz
$ 194,00 – $ 441,00Price range: $ 194,00 through $ 441,00
Altraz is a potent non-steroidal aromatase inhibitor specifically designed to support the treatment of breast cancer in postmenopausal women. The medication works by effectively lowering estrogen levels in the body, which helps to slow or stop the growth of certain types of breast tumors. It is primarily indicated for the adjuvant treatment of hormone receptor-positive early breast cancer to reduce the risk of recurrence. Additionally, Altraz is used as a first-line therapy for postmenopausal patients with locally advanced or metastatic breast cancer. This medication provides a reliable therapeutic option for managing hormone-sensitive conditions, helping patients improve their long-term health outcomes.
Active substance: Anastrozole
SKU:
Altraz
Category: Woman's Health
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM
Each dosage option has its own packaging choices.
Description
Altraz belongs to a class of medications known as non-steroidal aromatase inhibitors, containing the active substance anastrozole. It is indicated primarily for the adjuvant and advanced treatment of hormone receptor-positive breast cancer in postmenopausal women.
In the United States, Altraz is an oral prescription medication dispensed exclusively in accordance with federal regulations. Clinical evaluation and diagnostic testing, such as bone mineral density assessments, are standard components of therapeutic monitoring during treatment.
| Parameter | Details |
|---|---|
| Active ingredient | Anastrozole |
| Therapeutic class | Aromatase inhibitor (non-steroidal) |
| Dosage form | Oral tablet |
| Route of administration | Oral |
| Primary purpose | Hormone receptor-positive breast cancer therapy in postmenopausal women |
| Prescription status | Rx only (Prescription required under US federal law) |
Clinical Overview and Pharmacological Profile
Key Pharmacological Characteristics
How the drug works
The mechanism of action relies on the selective inhibition of the aromatase enzyme. In postmenopausal women, circulating estrogen is primarily produced through the conversion of adrenal androgens (such as androstenedione and testosterone) into estrone and estradiol by the aromatase enzyme complex in peripheral tissues. Altraz significantly lowers serum estradiol concentrations by blocking this enzyme. It displays no intrinsic progestogenic, androgenic, or estrogenic activity, and it does not interfere with adrenal corticosteroid synthesis, rendering aldosterone or cortisol replacement unnecessary during therapy.
What it’s used for
Altraz is indicated for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. It is also indicated as a first-line treatment for postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer. Additionally, it is used for advanced breast cancer in postmenopausal patients who experience disease progression following tamoxifen therapy. Any use of this medication in premenopausal women or for male endocrinological indications (such as gynecomastia management or fertility enhancement) is considered off-label and lacks formal approval by regulatory authorities.
What happens in the body
Following oral administration, anastrozole is absorbed rapidly into the systemic circulation, achieving peak plasma concentrations within two hours under fasting conditions. Food slightly decreases the rate of absorption but does not significantly alter the overall extent of bioavailability. The active compound undergoes extensive hepatic metabolism, primarily through N-dealkylation, hydroxylation, and glucuronidation, yielding inactive metabolites. The elimination half-life of anastrozole is approximately 50 hours, allowing for steady-state plasma concentrations to be achieved after approximately seven to ten days of once-daily dosing. Excretion occurs predominantly via hepatic clearance, with less than 10 percent of the dose recovered unchanged in the urine.
Dosing and Administration
Dosing schedule
The standard dosage for adult postmenopausal patients is one 1 mg tablet taken orally once daily. The tablet should be swallowed whole with water at approximately the same time each day to maintain stable plasma concentrations. Treatment is generally continued for a prolonged period; in the adjuvant setting, standard clinical protocol often extends therapy up to five years depending on disease progression and tolerance. No dosage adjustment is required for elderly patients or individuals with mild-to-moderate renal or hepatic impairment. However, caution and monitoring are advised in patients with severe hepatic dysfunction.
Compatibility with other medicines
Co-administration of Altraz with estrogen-containing therapies must be avoided, as exogenous estrogens negate the pharmacological action of the aromatase inhibitor. Furthermore, tamoxifen should not be administered concurrently with Altraz. Clinical studies indicate that tamoxifen reduces the plasma concentration of anastrozole when taken together, diminishing therapeutic efficacy without providing additional clinical benefit. Anastrozole exhibits low potential for clinically significant cytochrome P450-mediated drug interactions, but patients should inform their healthcare provider of all prescription medications, over-the-counter drugs, and dietary supplements currently in use.
What to avoid while taking it
Altraz can be administered with or without food, as food intake does not meaningfully affect clinical efficacy. Alcohol consumption should be limited or discussed with a physician. While alcohol does not directly alter the pharmacokinetics of anastrozole, both alcohol and aromatase inhibitors can induce dizziness, fatigue, and vasomotor symptoms such as hot flashes, potentially amplifying these adverse effects. Patients experiencing somnolence or dizziness should exercise caution when operating machinery or driving.
Safety, Precautions, and Common Questions
Critical Adverse Events and Red Flags
Adverse reactions
The administration of Altraz is associated with side effects related to estrogen deprivation. Common adverse reactions include hot flashes, joint pain (arthralgia), joint stiffness, arthritis, weakness, headache, back pain, dyspnea, nausea, rash, and peripheral edema. Lowering systemic estrogen levels accelerates bone resorption, which leads to a decrease in bone mineral density and an increased risk of osteopenia, osteoporosis, and bone fractures (particularly of the wrist, spine, and hip). Hypercholesterolemia and minor elevations in liver enzymes have also been observed during clinical monitoring.
Important precautions
Because Altraz causes a reduction in circulating estrogen levels, bone mineral density must be evaluated prior to initiating therapy and monitored at regular intervals throughout treatment. Patients with existing osteoporosis or at high risk for bone fractures should receive appropriate risk management and management strategies (such as bisphosphonate therapy or vitamin D and calcium supplementation) under medical direction. Patients with pre-existing ischemic heart disease should be monitored closely, as an increased incidence of cardiovascular events has been noted in clinical evaluation compared to alternative hormonal therapies.
Special populations
Altraz is strictly contraindicated in women who are or may become pregnant, as well as in nursing mothers. Estrogen deprivation during pregnancy presents a direct risk of fetal harm and potential embryo-fetal lethality. Altraz is not indicated for pediatric use, and its safety and effectiveness in pediatric populations have not been established. In elderly postmenopausal patients, no age-related dosage adjustments are required, though renal function and cardiovascular risk profiles should be routinely evaluated.
If you skip a dose
If a dose of Altraz is missed, it should be taken as soon as remembered on the same day. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely, and the normal dosing schedule resumed. Double doses should never be ingested to make up for a missed tablet, as this increases the likelihood of side effects without therapeutic benefit.
Red flags
While serious hypersensitivity reactions are infrequent, patients must remain aware of severe systemic signs requiring prompt intervention. The table below highlights critical symptoms that necessitate immediate emergency evaluation.
| Symptom Category | Immediate Clinical Concern |
|---|---|
| Allergic reaction / Anaphylaxis | Swelling of the face, lips, tongue, or throat; severe difficulty swallowing or breathing. |
| Severe dermatological reactions | Skin lesions, blistering, or peeling skin (indicative of Stevens-Johnson syndrome). |
| Cardiovascular events | Sudden severe chest pain, shortness of breath, pain radiating to the jaw or arm. |
| Thromboembolic signs | Sudden numbness, unilateral leg swelling, warmth, pain, or difficulty speaking. |
| Hepatic dysfunction | Yellowing of the skin or eyes (jaundice), severe right upper quadrant abdominal pain. |
Frequently Asked Questions
Is Altraz suitable for premenopausal women diagnosed with breast cancer?
No, Altraz is not indicated for premenopausal women. Its mechanism relies on inhibiting peripheral aromatase in patients whose ovaries are no longer producing estrogen. In premenopausal women with intact ovarian function, suppression of peripheral estrogen can trigger a compensatory rise in gonadotropins, stimulating the ovaries and rendering the treatment ineffective and inappropriate unless combined with specific ovarian suppression therapies under expert guidance.
How long does a typical course of treatment with Altraz last?
In the adjuvant treatment setting for early-stage hormone receptor-positive breast cancer, standard clinical regimens generally recommend continuous daily therapy for up to five years. The precise duration is determined individually by an oncologist based on clinical response, risk of recurrence, and overall tolerance to the medication.
What routine tests are necessary while taking Altraz?
Healthcare providers typically monitor bone mineral density using DEXA scans prior to treatment and periodically thereafter due to the risk of bone loss. Lipid panels are also checked regularly to screen for hypercholesterolemia. Routine liver function testing and general clinical monitoring are conducted to assess liver enzyme levels and cardiovascular health.
Can Altraz be taken at any time of day?
Yes, Altraz can be taken at any time of day, with or without food. However, it should be taken at approximately the same time every day to ensure consistent levels of the active medication in the bloodstream and to help establish a daily routine for adherence.
What should be done if joint pain becomes severe during therapy?
Joint pain (arthralgia) is a known side effect of aromatase inhibition due to reduced estrogen levels. Patients experiencing joint pain should inform their prescribing physician. A provider may evaluate the pain, recommend over-the-counter pain relievers, suggest exercise programs, or assess bone health, but therapy should not be discontinued without explicit medical advice.
In accordance with FDA requirements.
This text is for informational purposes only and does not constitute individual medical advice.
Additional information
| Dosage |
1mg |
|---|---|
| Package |
30 pills ,60 pills ,90 pills |
| Ενεργός Ουσία |
Related products
Alesse
$ 65,00 – $ 208,00Price range: $ 65,00 through $ 208,00
Active substance: ethinyloestradiol, Levonorgestrel
More Details
This product has multiple variants. The options may be chosen on the product page
Alkeran
$ 112,00 – $ 513,00Price range: $ 112,00 through $ 513,00
Active substance: Melphalan
More Details
This product has multiple variants. The options may be chosen on the product page
Careprost
$ 42,00 – $ 367,00Price range: $ 42,00 through $ 367,00
Active substance: Bimatoprost
More Details
This product has multiple variants. The options may be chosen on the product page
Clomid
$ 45,00 – $ 255,00Price range: $ 45,00 through $ 255,00
Active substance: Clomiphene
More Details
This product has multiple variants. The options may be chosen on the product page
Conjubrook
$ 215,00 – $ 705,00Price range: $ 215,00 through $ 705,00
Active substance: Conjugated Estrogens
More Details
This product has multiple variants. The options may be chosen on the product page
Doxylamine
$ 10,00 – $ 33,00Price range: $ 10,00 through $ 33,00
Active substance: Doxylamine succinate
More Details
This product has multiple variants. The options may be chosen on the product page
Estriol Cream
$ 13,00 – $ 93,00Price range: $ 13,00 through $ 93,00
Active substance: Estriol
More Details
This product has multiple variants. The options may be chosen on the product page
Etodolac
$ 46,00 – $ 390,00Price range: $ 46,00 through $ 390,00
Active substance: Etodolac
More Details
This product has multiple variants. The options may be chosen on the product page
